Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 15/20 | 0.56 |
| ▸ | CCKAR | P32238 | 11/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416283 | 0.90 | CCKBR (0.57) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL11831521 | 0.89 | MEN1 (0.62) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| Thiophene Carboxylic Acid SCHEMBL643248 | 0.88 | MEN1 (0.48) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL3965441 | 0.86 | MEN1 (0.49) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL641925 | 0.85 | LMNA (0.70) | MEN1KMT2ACCKBR | |
| SCHEMBL3183396 | 0.85 | CCKBR (0.48) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL3186746 | 0.85 | MEN1 (0.57) | MEN1KMT2ACCKBRCCKAR | |
| SCHEMBL11822036 | 0.81 | MEN1 (0.60) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL8211856 | 0.80 | MEN1 (0.77) | MEN1ALDH1A1KMT2ACCKBRCCKAR | |
| SCHEMBL20867074 | 0.80 | CCKBR (0.72) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | claimed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| EP-1727551-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| EP-1633348-B1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B sb 1 /sb RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2008-10-08 | — | — | EP | claimed |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-06-12 | — | — | US | claimed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | claimed |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-08-09 | — | — | US | claimed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | claimed |
| CN-1933841-A | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | ARROW THERAPEUTICS LTD (GB) | 2007-03-21 | — | — | CN | claimed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | claimed |
| JP-2006503054-A | — | — | 2006-01-26 | — | — | JP | claimed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-1539716-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Arrow Therapeutics Limited (GB) | 2005-06-15 | — | — | EP | claimed |
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | ELAN PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | claimed |
| WO-2004098589-A1 | 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004026843-A1 | BENZODIAZEPINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ARROW THERAPEUTICS LIMITED (GB) | 2004-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020659-A1 | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | BDKRB1, BDKRB2, BRS3 | MEN1 1010/4885ALDH1A1 3054/4885KMT2A 3940/4885 |
| US-20070185096-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | MEN1 4373/4885ALDH1A1 3840/4885KMT2A 3735/4885 |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | MEN1 4008/4885ALDH1A1 2127/4885KMT2A 2528/4885 |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | MEN1 3084/4885ALDH1A1 1301/4885KMT2A 1471/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | MEN1 3949/4885ALDH1A1 1931/4885KMT2A 2520/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | MEN1 4373/4885ALDH1A1 3840/4885KMT2A 3735/4885 |
| US-20080139536-A1 | Benzodiazepines for Treating or Preventing Rsv Infection | CNR1, CBR1, CBR3 | MEN1 4056/4885ALDH1A1 1328/4885KMT2A 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.